Mårs U, Larsson B S
Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
Pigment Cell Res. 1995 Aug;8(4):194-201. doi: 10.1111/j.1600-0749.1995.tb00663.x.
Thiouracil and a few related drugs are known to be melanoma-seeking agents owing to specific incorporation into nascent melanin. The melanin-affinic properties are apparently due to binding to intermediates, preferably dopaquinone, produced in the melanin synthetic pathway by tyrosinase-catalysed oxidation of tyrosine. In the present paper, in vitro screening methods have been used for the identification of possible melanoma seekers according to the above principle. The binding of test substance to dopaquinone suppressed dopachrome formation by the withdrawal of dopaquinone from the reaction of the mixture, and the decrease in dopachrome concentration was monitored spectrophotometrically at 475 nm. In order to eliminate false results caused by tyrosinase inhibition, which also will decrease the dopachrome concentration, the oxygen consumption was followed potentiometrically. To avoid the effect of tyrosinase inhibition on dopachrome formation, additional experiments with autoxidation of L-dopa in the presence of test substance were performed. Of the 22 substances (mainly thioureylenes and thioamides) studied, 4,5,6-triamino-2(H)- pyrimidinehtionsulfate, trithiocyanuric acid, 2-thiouracil, 6-methyl-2-thiouracil, and 4- amino-2-mercaptopyrimidine most effectively decreased the dopachrome formation with no or little inhibition of tyrosinase activity. They should therefore be regarded as potential melanoma seekers. In a complementary autoradiographic study on the uptake of the potent tyrosinase inhibitor mercaptobenzothiazole (MBT) in B 16 melanoma transplanted to mice, it was found that strong tyrosinase inhibition seems to decrease incorporation into melanin in vitro. MBT was partially accumulated in restricted areas of the tumor which may be explained by the molar dose injected.
已知硫脲嘧啶及一些相关药物是黑色素瘤靶向剂,因为它们能特异性地掺入新生黑色素中。其黑色素亲和特性显然是由于与黑色素合成途径中由酪氨酸酶催化酪氨酸氧化产生的中间体(最好是多巴醌)结合。在本文中,已根据上述原理采用体外筛选方法来鉴定可能的黑色素瘤靶向剂。测试物质与多巴醌的结合通过从混合物反应中去除多巴醌来抑制多巴色素的形成,并且通过分光光度法在475nm处监测多巴色素浓度的降低。为了消除由酪氨酸酶抑制引起的假结果(这也会降低多巴色素浓度),用电位法跟踪氧气消耗。为避免酪氨酸酶抑制对多巴色素形成的影响,在测试物质存在下进行了L-多巴自氧化的额外实验。在所研究的22种物质(主要是硫脲烯和硫代酰胺)中,4,5,6-三氨基-2(H)-嘧啶硫酸盐、三聚硫氰酸、2-硫脲嘧啶、6-甲基-2-硫脲嘧啶和4-氨基-2-巯基嘧啶最有效地降低了多巴色素的形成,而对酪氨酸酶活性没有或几乎没有抑制作用。因此,它们应被视为潜在的黑色素瘤靶向剂。在一项关于将强效酪氨酸酶抑制剂巯基苯并噻唑(MBT)摄取到移植到小鼠体内的B16黑色素瘤中的补充放射自显影研究中,发现强烈的酪氨酸酶抑制似乎会降低体外黑色素的掺入。MBT部分积聚在肿瘤的受限区域,这可能由注射的摩尔剂量来解释。